PRESTIGE CONSUMER HEALTHCARE INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, value, acquired, cost method for the quarter ending 2026-06-30 was $2.66M, a 93.20% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, value, acquired, cost method for the quarter ending 2026-03-31 was $754.00K, a 93.37% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, value, acquired, cost method for the quarter ending 2025-12-31 was $46.32M, a 1875.22% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, value, acquired, cost method for the quarter ending 2025-09-30 was $75.90M, a 536.09% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, value, acquired, cost method for fiscal 2026 was $162.09M, a 181.47% increase from fiscal 2025.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, value, acquired, cost method for fiscal 2025 was $57.59M, a 88.77% increase from fiscal 2024.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, value, acquired, cost method for fiscal 2024 was $30.51M, a 45.00% decline from fiscal 2023.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, value, acquired, cost method for fiscal 2023 was $55.47M, a 1802.13% increase from fiscal 2022.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-06-30 | $2.66M 10-Q · filed 2026-08-06 | $125.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $754.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-14 | $162.09M 10-K · filed 2026-05-14 |
| 2025-12-31 | $46.32M 10-Q · filed 2026-02-05 | $172.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $75.90M 10-Q · filed 2025-11-06 | $128.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $39.12M 10-Q · filed 2026-08-06 | $64.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-14 | $57.59M 10-K · filed 2026-05-14 |
| 2024-12-31 | $2.35M 10-Q · filed 2026-02-05 | $46.20M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-09-30 | $11.93M 10-Q · filed 2025-11-06 | $43.84M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-06-30 | $31.95M 10-Q · filed 2025-08-07 | $31.86M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-03-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-14 | $30.51M 10-K · filed 2026-05-14 |
| 2023-12-31 | -$23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-06 | $30.52M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-09-30 | -$46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $30.56M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-06-30 | $30.59M 10-Q · filed 2024-08-08 | $42.88M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-09 | $55.47M 10-K · filed 2025-05-09 |
| 2022-12-31 | $16.00K 10-Q · filed 2024-02-08 | $55.47M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-09-30 | $12.27M 10-Q · filed 2023-11-02 | $55.45M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-06-30 | $43.18M 10-Q · filed 2023-08-03 | $43.18M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-15 | $2.92M 10-K · filed 2024-05-15 |
| 2021-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-02 | $4.91M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-03 | $13.79M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-06-30 | $2.92M 10-Q · filed 2022-08-04 | $14.78M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-03-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-05 | $13.11M 10-K · filed 2023-05-05 |
| 2020-12-31 | $8.88M 10-Q · filed 2022-02-03 | $17.86M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-09-30 | $997.00K 10-Q · filed 2021-11-04 | $9.08M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-06-30 | $1.24M 10-Q · filed 2021-08-05 | $29.37M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-03-31 | $6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-06 | $57.70M 10-K · filed 2022-05-06 |
| 2019-12-31 | $94.00K 10-Q · filed 2021-02-04 | $50.95M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-09-30 | $21.29M 10-Q · filed 2020-11-05 | $50.86M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-06-30 | $29.57M 10-Q · filed 2020-08-06 | $29.57M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-07 | $52.26M 10-K · filed 2021-05-07 |
| 2018-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-06 | |
| 2018-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-10-31 | |
| 2018-06-30 | $52.26M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $1.07M 10-K · filed 2020-05-08 | |
| 2017-03-31 | $1.43M 10-K · filed 2019-05-13 | |
| 2016-03-31 | $1.69M 10-K · filed 2018-05-10 | |
| 2015-03-31 | $2.05M 10-K · filed 2017-05-17 | |
| 2014-03-31 | $744.00K 10-K · filed 2016-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |